HRT is Generally Safe to Start in Patients with Glaucoma
Based on current evidence, it is safe to initiate HRT in patients with glaucoma, and HRT may actually provide protective benefits by lowering intraocular pressure and potentially delaying glaucoma progression. The available guidelines do not list glaucoma as a contraindication to HRT, and recent research suggests hormonal therapy may be beneficial for ocular health 1.
Evidence Supporting Safety and Potential Benefits
IOP Reduction Effects
HRT demonstrates a significant reduction in intraocular pressure. A 2025 meta-analysis of 1,024 participants showed HRT lowered IOP by 3.84 mmHg compared to controls 2. This IOP reduction is clinically meaningful and could theoretically benefit glaucoma management, though it should not replace standard glaucoma therapy.
Delayed Disease Progression
Research indicates HRT may delay glaucoma onset rather than increase risk:
- Women using HRT for >5 years had glaucoma diagnosed 4.51 years later than non-users 3
- A Korean study found HRT users had a 7.9% lower glaucoma incidence, with the strongest protection in women aged 40-49 years 4
- Early initiation (within 1 year of menopause) provided the greatest protective effect 4
Contradictory Evidence Requires Context
One Finnish study reported increased glaucoma risk with HRT use 5, but this conflicts with multiple other studies showing protective effects. The Finnish study's methodology and population differences may explain this discrepancy. The weight of evidence, including a randomized controlled trial 6 and multiple large cohort studies 3, 4, 2, supports safety and potential benefit.
Clinical Decision Algorithm
Proceed with HRT initiation if:
- The patient has standard indications for HRT (menopausal symptoms, bone health)
- No absolute contraindications exist per standard HRT guidelines (history of breast cancer, active thromboembolism, active liver disease, unexplained vaginal bleeding) 1
- Glaucoma is being appropriately managed with standard therapy
Optimize the approach by:
- Initiating HRT within 1 year of menopause onset for maximum ocular benefit 4
- Considering estrogen-only therapy in women without a uterus, as this showed the most consistent glaucoma protection 6
- Planning for longer-term use (≥365 days) if tolerated, as extended duration correlates with greater IOP reduction 4, 2
Monitor appropriately:
- Continue standard glaucoma monitoring per established protocols (IOP checks, visual field testing, optic nerve assessment) 7
- Do not reduce glaucoma medications based solely on HRT initiation
- Assess for standard HRT side effects at 2-8 weeks 1
Important Caveats
HRT is not a glaucoma treatment. While it may provide ancillary IOP-lowering effects, patients must continue their prescribed glaucoma regimen 7. The primary indication for HRT should be menopausal symptom management or prevention of osteoporosis, not glaucoma control.
Race may modify effects. African-American women showed the strongest glaucoma risk reduction with estrogen-only therapy (51% risk reduction) 6, though combination estrogen-progesterone therapy did not show this racial difference.
Timing matters. The protective effect diminishes with later menopause age and delayed HRT initiation 3, 4. Women experiencing early menopause (age 40-49) derive the greatest ocular benefit 4.
Use standard HRT risk-benefit counseling. Discuss the established HRT risks (increased CHD events, stroke, pulmonary embolism, breast cancer with long-term use) against benefits (fracture reduction, colorectal cancer reduction, menopausal symptom relief) 1. The potential glaucoma benefit is an additional consideration but should not be the primary driver of the HRT decision.